Cargando…
Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells
Ganglioside GD2 is a well-established target expressed on multiple solid tumors, many of which are characterized by low treatment efficiency. Antibody-drug conjugates (ADCs) have demonstrated marked success in a number of solid tumors, and GD2-directed drug conjugates may also hold strong therapeuti...
Autores principales: | Kalinovsky, Daniel V., Kholodenko, Irina V., Kibardin, Alexey V., Doronin, Igor I., Svirshchevskaya, Elena V., Ryazantsev, Dmitriy Y., Konovalova, Maria V., Rozov, Fedor N., Larin, Sergey S., Deyev, Sergey M., Kholodenko, Roman V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860947/ https://www.ncbi.nlm.nih.gov/pubmed/36674755 http://dx.doi.org/10.3390/ijms24021239 |
Ejemplares similares
-
Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment–Drug Conjugates Carrying Maytansinoids DM1 and DM4
por: Kalinovsky, Daniel V., et al.
Publicado: (2023) -
Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
por: V. Kholodenko, Irina, et al.
Publicado: (2019) -
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
por: Kalinovsky, Daniel V, et al.
Publicado: (2022) -
Neuroblastoma Origin and Therapeutic Targets for Immunotherapy
por: Kholodenko, Irina V., et al.
Publicado: (2018) -
RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype
por: Sorokin, Maxim, et al.
Publicado: (2020)